FDA cancels panel review of Intra-Cellular’s schizophrenia drug, causing shares to tumble

Shares of Intra-Cellular Therapies (ITCI) fell sharply Tuesday afternoon after the Food and Drug Administration canceled an advisory committee meeting scheduled for next week to review the company’s lead drug, seeking approval as a new schizophrenia treatment.